AI-Enabled Optimization of Early- Phase Clinical Trials Pilot Program; Request for Information
NonrulemakingNoticeFDA-2026-N-4390-0001
Comments
121
Awaiting comments
Deadline
16 days
Closes Jun 30, 2026
Net support
+92%
Support minus oppose · campaigns included
+92% excluding campaigns
Document
Details
The document's own metadata, straight from regulations.gov.
- Posted
- Apr 29, 2026
- Comment period
- Apr 29, 2026 – Jun 30, 2026
- Agency
- Food and Drug Administration (FDA)
- FR Doc
- 2026-08281
Analysis
Overview
What the public is saying — stance, who's commenting, and the issues they raise.
Analyzed 120 of 121 comments
99%· analysis in progress
Stance breakdown
+92%
Net support
Support111Oppose1Other8Not yet analyzed1
Aggregates include form-letter campaigns. Excluding them, net support is +92% across organic comments.
Who commented
Breakdown by commenter type.
Academic
1
Business
76
Individual
27
Advocacy
14
Other
2
Not yet analyzed
1
Comments over time
Weekly arrivals, stacked by stance.
Posted Apr 29, 2026Deadline Jun 30, 2026
Support111Oppose1Other8
Support × commenter type
How each type splits across stance.
Issues raised
The docket's canonical issues. Select one to filter the Explorer.
Issues are identified as comment analysis progresses — nothing tagged on this document yet.
Comments
Explorer
Every mirrored comment — filter by stance, campaign, or issue.
Read all 121 comments
The Explorer — every comment with stance, commenter type, and AI summaries — is part of the paid plan. $180/month per seat, 30-day money-back guarantee.